{"brief_title": "Phase I Study of Human Von Willebrand Factor for Von Willebrand's Disease", "brief_summary": "OBJECTIVES: I. Evaluate the effect of a new von Willebrand factor concentrate on bleeding time, in vivo recovery, and circulating half-life of the infused factor in patients with von Willebrand's disease. II. Assess the safety of von Willebrand factor in these patients.", "detailed_description": "PROTOCOL OUTLINE: Patients receive 1 dose of von Willebrand factor concentrate. Timed blood studies are performed for the next 96 hours. Patients are followed every 2 weeks for 16 weeks, and at 24, 36, and 52 weeks.", "condition": ["Von Willebrand's Disease"], "intervention_type": ["Drug"], "intervention_name": ["von Willebrand factor"], "criteria": "PROTOCOL ENTRY CRITERIA: - von Willebrand's disease", "gender": "All", "minimum_age": "N/A", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "von Willebrand's disease", "mesh_term": ["Von Willebrand Diseases"], "id": "NCT00004667"}